Phase 3 study · Novartis · NCT07850752
Novartis's phase 3 zigakibart and atrasentan study for IgA nephropathy
About 340 adults are planned. Everyone gets zigakibart. Some also get atrasentan and others get a placebo in its place, and neither the participants nor the study doctors know which.
Get one email when it opens
We send an email only when the study starts enrolling or adds a US site. Your email is used for nothing else.
Free email alert
Hear when Novartis's phase 3 zigakibart and atrasentan study opens near you
One email when it starts enrolling or lists a new site, with the sites and how to reach the study team. Nothing else.
Opening and new sites for this study only. Stop anytime. We never share your email. Privacy policy
Check the main requirements privately
These questions restate the study's public listing in plain words. Your answers stay on this device and are never sent. You can print a one-page summary to go over with your nephrologist.
1. Are you 18 or older?
2. Has a kidney biopsy confirmed your IgA nephropathy in the last 10 years?
If no biopsy report from the last 10 years is available, the listing says a new biopsy may be done during screening.3. Is your latest urine protein-to-creatinine ratio (UPCR) at least 0.7g/g?
The study measures this itself on a 24-hour urine collection. Your nephrologist's office can tell you your latest number.4. Is your eGFR, the kidney filtering number on your blood test, 30 or higher?
5. Have you taken an ACE inhibitor or ARB blood pressure medicine at the highest dose you can handle, steadily, for at least 12 weeks?
Examples are lisinopril and losartan.6. Have you ever had heart failure, or fluid buildup such as fluid in the lungs or belly, or leg swelling that is hard to control?
The study team also checks for these, which are easier to go over with your nephrologist:
- Another cause of chronic kidney disease, or IgA nephropathy caused by another condition
- Active IgA vasculitis
- A rapid loss of kidney function (rapidly progressive glomerulonephritis)
- Nephrotic syndrome now
- A current severe infection, or repeated severe infections
- Other medicines such as an SGLT2 inhibitor, MRA or GLP-1 medicine, which must be at a steady dose for 12 weeks
Sites and contact
US sites from the public ClinicalTrials.gov record, refreshed every hour. Only the study team decides who can join.
No US sites are listed yet. Follow the study in step 1 and we'll email you the day sites are added.
Every site's own contact and the full eligibility list are on the official ClinicalTrials.gov listing for NCT07850752.
Questions people ask about Novartis's phase 3 zigakibart and atrasentan study
Is Novartis's phase 3 zigakibart and atrasentan study enrolling now?
ClinicalTrials.gov lists it as not yet recruiting, as of its last update there on 2026-09-30. Follow it on this page to get one email when it opens or adds US sites.
Where are the US sites for Novartis's phase 3 zigakibart and atrasentan study?
No US sites are listed yet. Following the study here sends one email the day US sites are added.
Who can join Novartis's phase 3 zigakibart and atrasentan study?
About 340 adults are planned. The main listed requirements are in the pre-check on this page, starting with: adults 18 and older. Only the study team decides who can join.
How do I contact the Novartis's phase 3 zigakibart and atrasentan study team?
The listing names this contact: Novartis Pharmaceuticals, 1-888-669-6682, novartis.email@novartis.com. Each site may also list its own contact on ClinicalTrials.gov.
Is Trial Friend part of this study?
No. Trial Friend is independent of this study and its sponsor, Novartis. This page restates the public listing in plain words, and nothing here is medical advice; talk with your nephrologist about whether a study is right for you.
From the public ClinicalTrials.gov record NCT07850752, last updated there 2026-09-30. Questions checked against the listing on November 9, 2026. Trial Friend is independent of this study and its sponsor, and is not a medical provider. Nothing here is medical advice; talk with your nephrologist about whether a study is right for you.